Associated Papers
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
41062696 (PubMed )
Supplement: 41586_2025_9584_MOESM6_ESM.xlsx › sitednds_oral
Kinase inhibitors in thyroid cancers.
Sukrithan V et al.
Endocrine Oncology (bristol, England), 2023
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.
Busaidy NL et al.
Thyroid : Official Journal of the American Thyroid Association, 2022
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.
Bagheri-Yarmand R et al.
Cancers, 2021
Genomic landscape of platinum resistant and sensitive testicular cancers.
Loveday C et al.
Nature Communications, 2020
32366847 (PubMed )
Supplement: 41467_2020_15768_MOESM7_ESM.xlsx › Supplementary_Data_4
The Rac GTPase in Cancer: From Old Concepts to New Paradigms.
Kazanietz MG et al.
Cancer Research, 2017
Anti-EGFR/BRAF-Tyrosine Kinase Inhibitors in Thyroid Carcinoma.
Papanikolaou V et al.
Cancer Diagnosis & Prognosis, 0
Select a paper to view details